Ceftriaxone

Ceftriaxone Impurities

Ceftriaxone is a third-generation cephalosporin antibiotic widely used to treat severe bacterial infections. Its impurity profile includes structurally related analogs, residual solvents, and degradation products formed under stress conditions such as hydrolysis, oxidation, and photolysis. Degradation pathways typically involve hydrolytic cleavage of the beta-lactam ring, oxidation of the aminothiazole side chain, and rearrangement of the triazinedione moiety. These impurities may affect the drug’s potency, stability, and safety. All impurities are structurally characterized and qualified in accordance with ICH guidelines for toxicological assessment and analytical validation.

Ceftriaxone EP Impurities

Pharmacopeial and non-pharmacopeial Ceftriaxone impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and long-term stability studies. EP traceable materials are supplied with validated analytical data, including purity, structural confirmation, and spectral characterization.

Ceftriaxone Related Compounds

Structurally related compounds and synthetic analogs associated with Ceftriaxone are included for use in impurity identification, toxicological qualification, and regulatory submission. These related substances are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations. They are essential for understanding the impurity profile and ensuring compliance with regulatory limits.

Ceftriaxone Impurity Reference Standards

Ceftriaxone impurity reference standards are provided with validated analytical data, including purity, NMR, MS, and full Certificates of Analysis. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.